BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35384902)

  • 1. MOC-31 Antibody Immunolabeling During Mohs Surgery.
    Bae E; Saap L; Breen C; Iwamoto S
    Dermatol Surg; 2022 Jun; 48(6):595-600. PubMed ID: 35384902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Ber-EP4 and MOC-31 in Basaloid Skin Tumor Detection.
    Gill P; Naugler C; Abi Daoud MS
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):584-588. PubMed ID: 29629953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-human epithelial antigen (Ber-EP4) helps define basal cell carcinoma masked by inflammation.
    Kist D; Perkins W; Christ S; Zachary CB
    Dermatol Surg; 1997 Nov; 23(11):1067-70. PubMed ID: 9391566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.
    Pai RK; West RB
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):202-6. PubMed ID: 19391212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens.
    Swanson PE; Fitzpatrick MM; Ritter JH; Glusac EJ; Wick MR
    J Cutan Pathol; 1998 Mar; 25(3):153-9. PubMed ID: 9550314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin.
    Tellechea O; Reis JP; Domingues JC; Baptista AP
    Am J Dermatopathol; 1993 Oct; 15(5):452-5. PubMed ID: 8238781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
    Krahl D; Sellheyer K
    J Cutan Pathol; 2007 Oct; 34(10):782-7. PubMed ID: 17880584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms.
    Jimenez FJ; Burchette JL; Grichnik JM; Hitchcock MG
    Mod Pathol; 1995 Oct; 8(8):854-8. PubMed ID: 8552575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOC-31/Ep-CAM immunoreactivity in Merkel cells and Merkel cell carcinomas.
    GarcĂ­a-Caballero T; Pintos E; Gallego R; Parrado C; Blanco M; Bjornhagen V; Forteza J; Beiras A
    Histopathology; 2003 Nov; 43(5):480-4. PubMed ID: 14636274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal cell carcinoma vs basaloid squamous cell carcinoma of the skin: an immunohistochemical reappraisal.
    Webb DV; Mentrikoski MJ; Verduin L; Brill LB; Wick MR
    Ann Diagn Pathol; 2015 Apr; 19(2):70-5. PubMed ID: 25702956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ber-EP4-positive phenotype differentiates actinic keratosis from superficial basal cell carcinoma.
    Tope WD; Nowfar-Rad M; Kist DA
    Dermatol Surg; 2000 May; 26(5):415-8. PubMed ID: 10816226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of immunohistochemical staining of bcl-2, Ber-EP4, CD10, CK20, and Ki-67 in differential diagnosis between trichoblastoma and basal cell carcinoma].
    Zhang ZC; Hu J; Kong YY; Ren M; Cai X
    Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):376-381. PubMed ID: 33831998
    [No Abstract]   [Full Text] [Related]  

  • 14. Reactivity with the EpCAM-specific antibodies MOC-31 and Ber-Ep4 in plasma cell neoplasms: a potential diagnostic pitfall in cytology samples.
    Weimholt RC; Sharifai N; Abro B; Vij K; Bernadt C
    J Am Soc Cytopathol; 2019; 8(5):265-269. PubMed ID: 31103372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ber-EP4 is a useful marker for follicular germinative cell differentiation of cutaneous epithelial neoplasms.
    Ansai S; Takayama R; Kimura T; Kawana S
    J Dermatol; 2012 Aug; 39(8):688-92. PubMed ID: 22300237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can basal cell carcinoma lateral border be determined by fluorescence diagnosis?: Verification by Mohs micrographic surgery.
    El Hoshy K; Bosseila M; El Sharkawy D; Sobhi R
    Photodiagnosis Photodyn Ther; 2016 Jun; 14():4-8. PubMed ID: 26790611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens.
    Najjar S; Gan Q; Stewart J; Sneige N
    Cancer Cytopathol; 2023 Apr; 131(4):245-253. PubMed ID: 36522809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical differentiation of basal cell epithelioma from cutaneous appendages using monoclonal anti-glycoprotein antibody TNKH1. Its application in Mohs' micrographic surgery.
    Setoyama M; Hashimoto K; Dinehart SM; Choi KC; Ishihara M; Predeteanu GS; Tronnier M; Pietruk T; Nakanishi T
    Cancer; 1990 Dec; 66(12):2533-40. PubMed ID: 2249196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases.
    Kuiper EM; van den Berge BA; Spoo JR; Kuiper J; Terra JB
    Clin Otolaryngol; 2018 Oct; 43(5):1321-1327. PubMed ID: 29953746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of non-melanoma skin cancers of the cutaneous perioral and vermilion lip treated by Mohs micrographic surgery.
    Queen D; Knackstedt T; Polacco MA; Collins LK; Lee K; Samie FH
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):305-311. PubMed ID: 30284728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.